A recent research report from CICC highlights the robust innovation capabilities demonstrated by Hong Kong-listed medical device companies collectively, with several enterprises poised to embark on a trajectory of profitability or accelerated performance growth. This year, these firms are anticipated to witness the launch of cutting-edge products and licensing opportunities stemming from technological advancements. Concurrently, a subset of 18A medical device companies, characterized by ample cash reserves, swift performance releases, and attractive valuations, have witnessed their share prices double since the year's inception. Moreover, leading medical device companies exhibiting high growth potential coupled with low valuations have also delivered strong performance. Regarding investments in A-share medical device companies, CICC expresses optimism towards stocks benefiting from optimized centralized procurement policies for medical devices, increased sales of innovative products, and substantial growth in international operations. It is anticipated that numerous enterprises will reach a performance inflection point in the second half of the year, with the potential for significant growth in the third quarter.